FEMY

Femasys's stock price has experienced significant fluctuations, decreasing by 64.40% over the last 12 months and showing a year-to-date return of -77.96%. As of September 15, 2026, the share price was $2.56, a decline of 65.41% from $7.40 on September 16, 2025. The company underwent a 20-to-1 reverse stock split on June 8, 2026. Recent events include FDA approval of a modular PMA submission approach for FemBloc in August 2026, Q2 2026 financial results in August 2026 showing sales declining 18.9% to $331,827 and a net loss of $4.5 million, alongside the completion of a $30 million private placement. In March 2026, Q1 2026 sales increased 24.5% year-over-year to $424,889 with a net income of $846,100. Femasys expanded its European commercial footprint with a Swiss distribution partner in February 2026, and Nasdaq granted the company a 180-day extension to regain compliance with the minimum bid price requirement in January 2026.